Hyperglucagonaemia in Patients With Type 2 Diabetes - Role of Glucagon Clearance
- Conditions
- Diabetes
- Interventions
- Biological: Glucagon
- Registration Number
- NCT02475421
- Lead Sponsor
- University Hospital, Gentofte, Copenhagen
- Brief Summary
The study aims to evaluate the elimination and degradation of glucagon in patients with type 2 diabetes compared to matched healthy subjects.
- Detailed Description
In the present project the investigators wish to identify whether the elimination and degradation of glucagon differ between healthy control subjects and patients with type 2 diabetes. Furthermore, the investigators wish to examine whether obesity is an independent factor for altered glucagon metabolism. Thus, by examining glucagon elimination in obese subjects with and without type 2 diabetes and in lean subjects with and without type 2 diabetes the investigators will be able to describe the metabolic clearance rate (MCR) of glucagon in a broad spectrum of individuals with different levels of insulin resistance and beta cell dysfunction.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 32
Patients with type 2 diabetes
- Caucasians above 35 years of age with diet or/and metformin-treated type 2 diabetes of at least 3 month duration (diagnosed according to World Health Organization (WHO) criteria
- BMI either below 27 or above 33 kg/m^2
- Normal haemoglobin
- Informed consent
Subjects with NGT
- Caucasians above 35 years of age
- BMI either below 27 or above 33 kg/m^2
- Normal HbA1c (according to WHO criteria)
- Normal haemoglobin
- Informed consent
Patients with type 2 diabetes
- Inflammatory bowel disease
- Operation within the last 3 months
- Severe kidney disease (eGFR < 60 ml/min)
- Severe liver disease (serum alanine aminotransferase (ALAT) and/or serum aspartate aminotransferase (ASAT) >2×normal values)
- Pregnancy and/or breastfeeding
- Age above 80 years
- Any condition that the investigators feel would interfere with trial participation
Subjects with NGT
- Diabetes
- Prediabetes (impaired FPG or HbA1c above 42 mmol/mol)
- First-degree relatives with diabetes
- Inflammatory bowel disease
- Intestinal resection
- Severe kidney disease (eGFR < 60 ml/min)
- Liver disease (ALA T and/or serum ASA T >2×normal values)
- Pregnancy and/or breastfeeding
- Age above 80 years Any condition that the investigators feel would interfere with trial participation
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Healthy, lean subjects Glucagon Healthy subjects with BMI \< 27 kg/m\^2 Healthy, obese subjects Glucagon Healthy subjects with BMI \> 33 kg/m\^2 Diabetic, lean subjects Glucagon Diabetic subjects with BMI \< 27 kg/m\^2 Diabetic, obese subjects Glucagon Diabetic subjects with BMI \> 33 kg/m\^2
- Primary Outcome Measures
Name Time Method Metabolic clearance rate of glucagon -30, -15, 0, 5, 10, 20, 50, 55, 60, 62, 64, 66, 68, 70, 75, 80, 85, 90, 120 minutes
- Secondary Outcome Measures
Name Time Method Gut and pancreatic hormones -30, -15, 0, 5, 10, 20, 50, 55, 60, 62, 64, 66, 68, 70, 75, 80, 85, 90, 120 minutes Blood glucose -30, -15, 0, 5, 10, 20, 50, 55, 60, 62, 64, 66, 68, 70, 75, 80, 85, 90, 120 minutes Basic metabolic rate -30, -15, 0, 5, 10, 20, 50, 55, 60, 62, 64, 66, 68, 70, 75, 80, 85, 90, 120 minutes Satiety, hunger, appetite - measured with visual analogue scales (VAS) -30, -15, 0, 5, 10, 20, 50, 55, 60, 62, 64, 66, 68, 70, 75, 80, 85, 90, 120 minutes Half life of glucagon -30, -15, 0, 5, 10, 20, 50, 55, 60, 62, 64, 66, 68, 70, 75, 80, 85, 90, 120 minutes The volume of distribution of glucagon -30, -15, 0, 5, 10, 20, 50, 55, 60, 62, 64, 66, 68, 70, 75, 80, 85, 90, 120 minutes
Trial Locations
- Locations (1)
Center for Diabetes Research, Department of Medicine, Gentofte Hospital
🇩🇰Hellerup, Copenhagen, Denmark